PMID- 33532180 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231110 IS - 2211-3835 (Print) IS - 2211-3843 (Electronic) IS - 2211-3835 (Linking) VI - 11 IP - 1 DP - 2021 Jan TI - Recent advances in drug delivery systems for targeting cancer stem cells. PG - 55-70 LID - 10.1016/j.apsb.2020.09.016 [doi] AB - Cancer stem cells (CSCs) are a subpopulation of cancer cells with functions similar to those of normal stem cells. Although few in number, they are capable of self-renewal, unlimited proliferation, and multi-directional differentiation potential. In addition, CSCs have the ability to escape immune surveillance. Thus, they play an important role in the occurrence and development of tumors, and they are closely related to tumor invasion, metastasis, drug resistance, and recurrence after treatment. Therefore, specific targeting of CSCs may improve the efficiency of cancer therapy. A series of corresponding promising therapeutic strategies based on CSC targeting, such as the targeting of CSC niche, CSC signaling pathways, and CSC mitochondria, are currently under development. Given the rapid progression in this field and nanotechnology, drug delivery systems (DDSs) for CSC targeting are increasingly being developed. In this review, we summarize the advances in CSC-targeted DDSs. Furthermore, we highlight the latest developmental trends through the main line of CSC occurrence and development process; some considerations about the rationale, advantages, and limitations of different DDSs for CSC-targeted therapies were discussed. CI - (c) 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. FAU - Duan, Hongxia AU - Duan H AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. FAU - Liu, Yanhong AU - Liu Y AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. FAU - Gao, Zhonggao AU - Gao Z AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. FAU - Huang, Wei AU - Huang W AD - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. AD - Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. LA - eng PT - Journal Article PT - Review DEP - 20201002 PL - Netherlands TA - Acta Pharm Sin B JT - Acta pharmaceutica Sinica. B JID - 101600560 PMC - PMC7838023 OTO - NOTNLM OT - ABC, ATP binding cassette OT - AFN, apoferritin OT - ALDH, aldehyde dehydrogenase OT - BM-MSCs-derived Exos, bone marrow mesenchymal stem cells-derived exosomes OT - Biomarker OT - CAFs, cancer-associated fibroblasts OT - CL-siSOX2, cationic lipoplex of SOX2 small interfering RNA OT - CMP, carbonate-mannose modified PEI OT - CQ, chloroquine OT - CSCs, cancer stem cells OT - Cancer stem cells OT - Cancer treatment OT - Cellular level OT - DCLK1, doublecortin-like kinase 1 OT - DDSs, drug delivery systems OT - DLE, drug loading efficiency OT - DOX, doxorubicin OT - DQA-PEG2000-DSPE, dequlinium and carboxyl polyethylene glycol-distearoylphosphatidylethanolamine OT - Dex, dexamethasone OT - Drug delivery systems OT - ECM, extracellular matrix OT - EMT, epithelial-mesenchymal transition OT - EPND, nanodiamond-Epirubicin drug complex OT - EpCAM, epithelial cell adhesion molecule OT - GEMP, gemcitabine monophosphate OT - GLUT1, glucose ligand to the glucose transporter 1 OT - Glu, glucose OT - HCC, hepatocellular carcinoma OT - HH, Hedgehog OT - HIF1alpha, hypoxia-inducible factor 1-alpha OT - HNSCC, head and neck squamous cell carcinoma OT - IONP, iron oxide nanoparticle OT - LAC, lung adenocarcinoma OT - LNCs, lipid nanocapsules OT - MAPK, mitogen-activated protein kinase OT - MB, methylene blue OT - MDR, multidrug resistance OT - MNP, micellar nanoparticle OT - MSNs, mesoporous silica nanoparticles OT - Molecular level OT - NF-kappaB, nuclear factor-kappa B OT - Nav, navitoclax OT - Niche OT - PBAEs, poly(beta-aminoester) OT - PDT, photodynamic therapy OT - PEG-PCD, poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene carbonate-graft-dodecanol) OT - PEG-PLA, poly(ethylene glycol)-b-poly(d,l-lactide) OT - PEG-b-PLA, poly(ethylene glycol)-block-poly(d,l-lactide) OT - PLGA, poly(ethylene glycol)-poly(d,l-lactide-co-glycolide) OT - PTX, paclitaxel OT - PU-PEI, polyurethane-short branch-polyethylenimine OT - SLNs, solid lipid nanoparticles OT - SSCs, somatic stem cells OT - Sali-ABA, 4-(aminomethyl) benzaldehyde-modified Sali OT - TNBC, triple negative breast cancer OT - TPZ, tirapazamine OT - Targeting strategies OT - cRGD, cyclic Arg-Gly-Asp OT - iTEP, immune-tolerant, elastin-like polypeptide OT - mAbs, monoclonal antibodies OT - mPEG-b-PCC-g-GEM-g-DC-g-CAT, poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylenecarbonate-graft-dodecanol-graft-cationic ligands) OT - ncRNA, non-coding RNAs OT - uPAR, urokinase plasminogen activator receptor EDAT- 2021/02/04 06:00 MHDA- 2021/02/04 06:01 PMCR- 2020/10/02 CRDT- 2021/02/03 05:59 PHST- 2020/04/24 00:00 [received] PHST- 2020/06/25 00:00 [revised] PHST- 2020/07/12 00:00 [accepted] PHST- 2021/02/03 05:59 [entrez] PHST- 2021/02/04 06:00 [pubmed] PHST- 2021/02/04 06:01 [medline] PHST- 2020/10/02 00:00 [pmc-release] AID - S2211-3835(20)30732-2 [pii] AID - 10.1016/j.apsb.2020.09.016 [doi] PST - ppublish SO - Acta Pharm Sin B. 2021 Jan;11(1):55-70. doi: 10.1016/j.apsb.2020.09.016. Epub 2020 Oct 2.